A Closer Look at the Denial of Suorin and Blu PLUS+ Products: FDA’s Robust Regulation of E-Cigarettes

In a landmark decision impacting the e-cigarette industry, the U.S. Food and Drug Administration (FDA) issued Marketing Denial Orders (MDOs) against two prominent vaping brands, Suorin and Blu PLUS+, on January 19, 2024. This move by the FDA underscores its strict regulatory stance on e-cigarettes and vaping products, emphasizing public health concerns and regulatory compliance.

Suorin, under Shenzhen Youme Information Technology Co. Ltd., faced denial for its e-cigarette products due to a significant lack of evidence concerning abuse liability. This aspect is critical in the FDA’s evaluation process, as it determines the potential for substance misuse and public health impact. On the other hand, Blu PLUS+ products, by Fontem US, LLC, were rejected for their insufficient disclosure of ingredient information and failure to provide adequate data on harmful constituent yields and abuse liability. These deficiencies highlight the FDA’s rigorous standards for market authorization, focusing on comprehensive product information and safety assessment.

The FDA’s decision aligns with its ongoing efforts to protect public health, especially considering the rising use of e-cigarettes among younger demographics. National surveys have pointed to the growing prevalence of e-cigarette use among middle and high school students, raising concerns about nicotine addiction and other health risks associated with vaping.

This regulatory action serves as a crucial reminder to e-cigarette manufacturers about the importance of meeting stringent public health standards. The FDA’s enforcement of these standards is pivotal in controlling the marketing and distribution of e-cigarette products, ensuring they do not pose undue risks to consumers, particularly the youth.